Joachim Alexander, Schwerd Tobias, Hölz Hannes, Sokollik Christiane, Konrad Lukas Alfons, Jordan Alexander, Lanzersdorfer Roland, Schmidt-Choudhury Anjona, Hünseler Christoph, Adam Rüdiger
Klinik für Kinder- und Jugendmedizin, Uniklinik Köln, Köln, Germany.
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Klinikum der Universtität München, LMU München, München, Germany.
Z Gastroenterol. 2022 Jun;60(6):963-969. doi: 10.1055/a-1801-0284. Epub 2022 May 9.
The human microbiome and especially the gastrointestinal microbiota are associated with health and disease. Disturbance in the composition or function of fecal microbiota (dysbiosis) plays a role in the development of pediatric gastrointestinal diseases. Fecal microbiota transfer (FMT) is a special intervention, where microbiota are transferred from a healthy donor.In this review we describe the current state of knowledge for FMT in pediatric patients. There is satisfactory evidence concerning FMT in patients with recurrent infection. For inflammatory bowel disease, few studies show a potential benefit.Adverse events occurred frequently in clinical studies, but were mostly mild and transient. There are hardly any data on long-term side effects of FMT, which are particularly significant for pediatrics. In practice, there is uncertainty as to which application route, dosage or frequency should be used. Legally, donor stool is considered a drug in German-speaking countries, for which no marketing authorization exists.In conclusion, knowledge about physiology, efficacy and side effects of FMT is insufficient and legal concerns complicate its implementation. More studies on this topic are needed urgently.